Biomet U.K. facility cited for design transfer deficiencies in FDA warning letter.
This article was originally published in The Gray Sheet
BIOMET U.K. PLANT DESIGN TRANSFER DEFICIENCIES CITED BY FDA in a Nov. 1 warning letter to the Bridgen, U.K. facility. Stemming from a July 29-31 inspection, the two-page warning letter says that Biomet failed "to establish and implement specification control measures to assure that the design basis for the device and packaging is correctly translated into approved specifications." The citations relate to Biomet's production of Brooker-Wills orthopedic cancellous screws.
You may also be interested in...
Biomet says it will consider alternative production sites for its Stanmore hip, Copeland shoulder and Oxford knee implantable devices if the company and FDA are unable to resolve sterilization and validation issues in a timely fashion at a UK facility identified by the agency in a Feb. 19 warning letter
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.